TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 2476520

Group type: EXPERIMENTAL
Intervention: Aclatonium (300 mg)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study: 20005

Group type: EXPERIMENTAL
Intervention: Dibencozide
Number of subjects: 0

Group type: COMPARATOR
Intervention: Corticosteroids
Number of subjects: 0
Study: 30694377

Group type: EXPERIMENTAL
Intervention: MRI through intravenous gadolinium administration (IV-Gd)
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: oVEMP
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: cVEMP
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: PTA
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Caloric tests
Number of subjects: 56
Study: 28362843

Group type: EXPERIMENTAL
Intervention: Anodal transcranial Direct Current Stimulation to the right DLPFC
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (no stimulation)
Number of subjects: 0
Study: 26124497

Group type: EXPERIMENTAL
Intervention: High-dose methotrexate (HD-MTX)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Capizzi methotrexate (C-MTX)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Intensified therapy for MRD >0.1%
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: End-induction MRD <0.01%
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Conversion from MRD positive to negative by end consolidation
Number of subjects: 0
Study: 22888759

Group type: EXPERIMENTAL
Intervention: Supervised kinesiotherapy aimed at improvement of muscle activity and headache symptoms releasing.
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group (not specified in detail).
Number of subjects: 40
Study: 21209585

Group type: EXPERIMENTAL
Intervention: Stress management training (coping strategies, mental rehearsal, relaxation)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 16
Study: 17914032

Group type: EXPERIMENTAL
Intervention: pioglitazone (45 mg)
Number of subjects: 31

Group type: COMPARATOR
Intervention: metformin (2,000 mg)
Number of subjects: 31
Study: 17243597

Group type: EXPERIMENTAL
Intervention: Total-etch three-step (TE3) dentin adhesive system with correct application
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Aggressive drying of primer
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Short application of primer by immediate drying
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: No drying of primer
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: No primer application
Number of subjects: 70
Study: 15280105

Group type: EXPERIMENTAL
Intervention: L-arginine 3 g daily orally for 20 days
Number of subjects: 108

Group type: COMPARATOR
Intervention: Control (no treatment)
Number of subjects: 108
Study: 11762418

Group type: EXPERIMENTAL
Intervention: Monoclonal antibodies (e.g., Rituxan, Mylotarg, Campath)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Monoclonal antibodies as monotherapy or in combination with conventional chemotherapies
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Engineered antibodies
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Antibody engineering
Number of subjects: 0
Study: 9274891

Group type: EXPERIMENTAL
Intervention: Cyclical etidronate therapy
Number of subjects: 152

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 152
Study: 7829762

Group type: EXPERIMENTAL
Intervention: brofaromine 150 mg daily (n = 111)
Number of subjects: 220

Group type: COMPARATOR
Intervention: placebo (n = 109)
Number of subjects: 220

Group type: EXPERIMENTAL
Intervention: brofaromine 150 mg daily
Number of subjects: 220
Study: 3284501

Group type: EXPERIMENTAL
Intervention: Tetracycline hydrochloride (n = 23)
Number of subjects: 53

Group type: COMPARATOR
Intervention: Isotonic saline (n = 30)
Number of subjects: 53
Study: 30149282

Group type: EXPERIMENTAL
Intervention: Untouched selfie
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: Retouched selfie
Number of subjects: 110

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 110
Study: 27998964

Group type: EXPERIMENTAL
Intervention: Dasatinib 100 mg daily plus gemcitabine 1000 mg/m2 (30-min IV infusion) on days 1, 8, 15 of a 28-day cycle
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo plus gemcitabine 1000 mg/m2 (30-min IV infusion) on days 1, 8, 15 of a 28-day cycle
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Dasatinib plus gemcitabine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo plus gemcitabine
Number of subjects: 0
Study: 26165360

Group type: EXPERIMENTAL
Intervention: Skin staples (Leukosan® SkinStapler PTW‐35, BSN, Germany)
Number of subjects: 231

Group type: COMPARATOR
Intervention: Continuous 3.0 intradermal non-absorbable polypropylene suture (Prolene™ 0, Ethicon Inc. Somerville, New Jersey, USA)
Number of subjects: 231
Study: 23715754

Group type: EXPERIMENTAL
Intervention: GFT505 (80 mg/day)
Number of subjects: 22
Study: 21393146

Group type: EXPERIMENTAL
Intervention: Routine laboratory monitoring
Number of subjects: 0

Group type: COMPARATOR
Intervention: Clinically driven monitoring
Number of subjects: 0
Study: 18435857

Group type: EXPERIMENTAL
Intervention: Interactive booklet on respiratory tract infections
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 0
Study: 16574037

Group type: EXPERIMENTAL
Intervention: P‐ERMS once daily in AM or PM for a 4‐week treatment period
Number of subjects: 1428
Study: 14599939

Group type: EXPERIMENTAL
Intervention: Hepatectomy after pre-ligation of the hepatic inflow and outflow blood vessels of the lesioned liver lobe (Group B)
Number of subjects: 68

Group type: COMPARATOR
Intervention: Pringle's maneuver (Group A)
Number of subjects: 68
Study: 11007154

Group type: EXPERIMENTAL
Intervention: Thematic model of condom use outcomes
Number of subjects: 4638

Group type: EXPERIMENTAL
Intervention: Self-concept and pleasure
Number of subjects: 4638

Group type: EXPERIMENTAL
Intervention: Protection and interaction
Number of subjects: 4638
Study: 9402690

Group type: EXPERIMENTAL
Intervention: Tacrolimus and MMF
Number of subjects: 18

Group type: COMPARATOR
Intervention: CsA with MMF (1.0 g bid)
Number of subjects: 18

Group type: COMPARATOR
Intervention: CsA with MMF (1.5 g bid)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: MPA and tacrolimus
Number of subjects: 18
Study: 8210830

Group type: EXPERIMENTAL
Intervention: Mixed Poisson-gamma regression method
Number of subjects: 0

Group type: COMPARATOR
Intervention: Quasi-likelihood method
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Thall method
Number of subjects: 0

Group type: COMPARATOR
Intervention: Zeger and Liang method
Number of subjects: 0
Study: 3535134

Group type: EXPERIMENTAL
Intervention: Piperacillin
Number of subjects: 298

Group type: EXPERIMENTAL
Intervention: Cephalothin
Number of subjects: 298

Group type: EXPERIMENTAL
Intervention: Cefoxitin
Number of subjects: 298
Study: 31135579

Group type: EXPERIMENTAL
Intervention: Opportunistic salpingectomy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Salpingo-oophorectomy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Concomitant salpingectomy
Number of subjects: 0
Study: 29638148

Group type: EXPERIMENTAL
Intervention: Esomeprazole 40 mg IV infusion twice daily for up to 14 days
Number of subjects: 274

Group type: COMPARATOR
Intervention: Cimetidine 50 mg/h continuous IV infusion following an initial bolus of 300 mg for up to 14 days
Number of subjects: 274
Study: 30182671

Group type: EXPERIMENTAL
Intervention: Levocetirizine
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Montelukast
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Combination of Levocetirizine and Montelukast
Number of subjects: 75

Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 75
Study: 25560825

Group type: EXPERIMENTAL
Intervention: Priming legacy motives
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Legacy motivation
Number of subjects: 0
Study: 23535873

Group type: EXPERIMENTAL
Intervention: Beta-alanine (6.4 g · d(‐1) for 4 weeks)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Sodium bicarbonate
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Beta-alanine with sodium bicarbonate
Number of subjects: 20
Study: 20495586

Group type: EXPERIMENTAL
Intervention: Cervical interlaminar epidural injections of local anesthetic (lidocaine 0.5%, 5 mL)
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Cervical interlaminar epidural injections with 0.5% lidocaine (4 mL) mixed with 1 mL of non-particulate betamethasone
Number of subjects: 70
Study: 17983686

Group type: EXPERIMENTAL
Intervention: Fluticasone
Number of subjects: 108

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 108
Study: 15985032

Group type: EXPERIMENTAL
Intervention: Ciclopirox 0.77% gel applied twice daily
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Ciclopirox 0.77% gel applied once daily
Number of subjects: 100

Group type: COMPARATOR
Intervention: Vehicle (placebo)
Number of subjects: 100
Study: 12325402

Group type: EXPERIMENTAL
Intervention: Massage therapy (two 40‐min sessions per week for 5 weeks)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Exercise group (range of motion exercise routine targeting arms, neck, shoulders, and back, 2 times per week for 5 weeks)
Number of subjects: 20
Study: 10526701

Group type: EXPERIMENTAL
Intervention: Metoprolol CR/XL
Number of subjects: 3991

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3991
Study: 7795096

Group type: EXPERIMENTAL
Intervention: Ciprofloxacin (500 mg)
Number of subjects: 82

Group type: COMPARATOR
Intervention: TMP-SMZ (640 mg/3,200 mg)
Number of subjects: 82
Study: 2343070

Group type: EXPERIMENTAL
Intervention: 10 mg haloperidol
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: reduced haloperidol
Number of subjects: 6
Study: 7000476

Group type: EXPERIMENTAL
Intervention: 250 mg chenodeoxycholic acid (CDC)/day
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: 375 mg chenodeoxycholic acid (CDC)/day
Number of subjects: 35

Group type: COMPARATOR
Intervention: 375 mg CDC/day (after 6 months for placebo patients)
Number of subjects: 35
Study: 31568489

Group type: EXPERIMENTAL
Intervention: LLIN + IRS
Number of subjects: 34548

Group type: EXPERIMENTAL
Intervention: LLIN alone
Number of subjects: 34548

Group type: EXPERIMENTAL
Intervention: IRS alone
Number of subjects: 34548

Group type: COMPARATOR
Intervention: Control
Number of subjects: 34548
Study: 27646824

Group type: EXPERIMENTAL
Intervention: Wireless, Accelerometry‐Triggered Functional Electrical Stimulation (WAFES)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Conventional physical therapy (CPT)
Number of subjects: 20
Study: 26180108

Group type: EXPERIMENTAL
Intervention: Intensive glucose target of 100‐140 mg/dL (n = 151)
Number of subjects: 302

Group type: COMPARATOR
Intervention: Conservative glucose target of 141‐180 mg/dL (n = 151)
Number of subjects: 302

Group type: EXPERIMENTAL
Intervention: Intensive regimen in patients without diabetes
Number of subjects: 302

Group type: COMPARATOR
Intervention: Conservative regimen in patients without diabetes
Number of subjects: 302

Group type: EXPERIMENTAL
Intervention: Intensive regimen in patients with diabetes
Number of subjects: 302

Group type: COMPARATOR
Intervention: Conservative regimen in patients with diabetes
Number of subjects: 302
Study: 24375220

Group type: EXPERIMENTAL
Intervention: Oral Targin (oxycodone-hydrochloride and naloxone hydrochloride-dihydrate)
Number of subjects: 51

Group type: COMPARATOR
Intervention: Patient-controlled IV morphine
Number of subjects: 51
Study: 22934858

Group type: EXPERIMENTAL
Intervention: Long thoracic nerve (LTN) block
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 0
Study: 19900154

Group type: EXPERIMENTAL
Intervention: Exercise
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Pravastatin
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Combination of Exercise and Pravastatin
Number of subjects: 34

Group type: COMPARATOR
Intervention: Control (no intervention)
Number of subjects: 34
Study: 17609623

Group type: EXPERIMENTAL
Intervention: Prophylaxis
Number of subjects: 0

Group type: COMPARATOR
Intervention: Episodic therapy
Number of subjects: 0
Study: 10636271

Group type: EXPERIMENTAL
Intervention: Thrombolytic therapy for acute myocardial infarction (AMI)
Number of subjects: 1889

Group type: EXPERIMENTAL
Intervention: Age, systolic blood pressure, heart rate, and Killip class upon presentation
Number of subjects: 1889

Group type: EXPERIMENTAL
Intervention: Scoring system based on age and physical examination
Number of subjects: 1889
Study: 8731641

Group type: EXPERIMENTAL
Intervention: Sodium picosulphate solution (Picolax)
Number of subjects: 59

Group type: COMPARATOR
Intervention: Polyethylene glycol bowel lavage solution (Klean Prep)
Number of subjects: 59
Study: 1413580

Group type: COMPARATOR
Intervention: Drugs only
Number of subjects: 126

Group type: EXPERIMENTAL
Intervention: Drugs and graded walking
Number of subjects: 126

Group type: EXPERIMENTAL
Intervention: Drugs and low-effort bicycle exercise
Number of subjects: 126
Study: 4054193

Group type: EXPERIMENTAL
Intervention: Metoprolol
Number of subjects: 17

Group type: COMPARATOR
Intervention: Atenolol
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Discontinuation of original lipophilic beta-blocker
Number of subjects: 17
Study: 30994855

Group type: EXPERIMENTAL
Intervention: Paliperidone palmitate 3-month formulation (PP3M)
Number of subjects: 114

Group type: COMPARATOR
Intervention: Paliperidone palmitate 1-month formulation (PP1M)
Number of subjects: 114

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 114
Study: 29322610

Group type: EXPERIMENTAL
Intervention: semaglutide 0.5 mg
Number of subjects: 601

Group type: EXPERIMENTAL
Intervention: semaglutide 1.0 mg
Number of subjects: 601

Group type: COMPARATOR
Intervention: additional OAD
Number of subjects: 601
Study: 26795423

Group type: EXPERIMENTAL
Intervention: Nurse-led proactive care intervention over 2 years
Number of subjects: 558

Group type: EXPERIMENTAL
Intervention: Nurse-led proactive care intervention (10 sessions)
Number of subjects: 558

Group type: COMPARATOR
Intervention: General practitioner (GP) treatment as usual
Number of subjects: 558
Study: 24697877

Group type: EXPERIMENTAL
Intervention: Atorvastatin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: L-NMMA (during atorvastatin and placebo treatment)
Number of subjects: 0
Study: 22332798

Group type: EXPERIMENTAL
Intervention: Metformin (achieved glycemic control with HbA1c ≤ 8% for at least 2 months)
Number of subjects: 704
Study: 20009090

Group type: EXPERIMENTAL
Intervention: 20 mg/day rimonabant
Number of subjects: 368

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 368
Study: 18685543

Group type: EXPERIMENTAL
Intervention: Additional spermicide
Number of subjects: 145

Group type: COMPARATOR
Intervention: Control (condoms alone)
Number of subjects: 145
Study: 15747005

Group type: EXPERIMENTAL
Intervention: Gold-plating technique in Ni-Cr metal ceramic crown
Number of subjects: 64

Group type: COMPARATOR
Intervention: No treatment (control group)
Number of subjects: 64
Study: 12795771

Group type: EXPERIMENTAL
Intervention: Alefacept 7.5 mg IV
Number of subjects: 1002

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1002

Group type: EXPERIMENTAL
Intervention: Alefacept 7.5 mg IV (after second course)
Number of subjects: 1002
Study: 10596705

Group type: EXPERIMENTAL
Intervention: Inhaled fluticasone (500 microg b.i.d., for three weeks)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Nonsteroid medication (control group)
Number of subjects: 26
Study: 8739860

Group type: EXPERIMENTAL
Intervention: Oxy- and xylometazoline nasal sprays
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Topical vasoconstrictors
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Benzalkonium chloride in nasal decongestant solutions
Number of subjects: 0
Study: 1924660

Group type: EXPERIMENTAL
Intervention: Venlafaxine 25 mg t.i.d.
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: Venlafaxine 75 mg t.i.d.
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: Venlafaxine 125 mg t.i.d.
Number of subjects: 93

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 93
Study: 29426270

Group type: EXPERIMENTAL
Intervention: Evening primrose oil (EvPO) 1000 mg, twice daily for 7 days
Number of subjects: 80

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study: 27005564

Group type: EXPERIMENTAL
Intervention: Case Management (CM)
Number of subjects: 120
Study: 25450583

Group type: EXPERIMENTAL
Intervention: 100mg/day coQ10 capsules
Number of subjects: 44

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 44
Study: 22189825

Group type: EXPERIMENTAL
Intervention: Antiglaucomatous therapy (various medications including metipranolol 0.3%, timolol 0.5%, dorzolamid, brinzolamid, brimonidine, bimatoprost, travoprost, and latanoprost)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Monotherapy and dual therapy (two substances in one drug)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Prostaglandin agonists (PGA)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Timolol plus brinzolamide (combined therapy)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Timolol plus travoprost
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Beta-blockers (BB)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Not preserved eye drops (PGAs)
Number of subjects: 0
Study: 20211296

Group type: EXPERIMENTAL
Intervention: Enteric-coated aspirin, 100 mg/d
Number of subjects: 14466

Group type: COMPARATOR
Intervention: No aspirin
Number of subjects: 14466
Study: 18551533

Group type: EXPERIMENTAL
Intervention: Nasogastric or nasojejunal decompression
Number of subjects: 717

Group type: COMPARATOR
Intervention: No decompression
Number of subjects: 717
Study: 15629208

Group type: EXPERIMENTAL
Intervention: Parkinson's disease patients
Number of subjects: 18

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 18
Study: 12592333

Group type: EXPERIMENTAL
Intervention: ATRA --> CT
Number of subjects: 306

Group type: COMPARATOR
Intervention: ATRA + CT
Number of subjects: 306
Study: 10368815

Group type: EXPERIMENTAL
Intervention: Flaxseed (5 g/day)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Flaxseed (10 g/day)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Control (0 g/day)
Number of subjects: 28
Study: 8768018

Group type: EXPERIMENTAL
Intervention: Total enteral nutrition
Number of subjects: 24

Group type: COMPARATOR
Intervention: Mixed parenteral and enteral nutrition
Number of subjects: 24
Study: 1860749

Group type: EXPERIMENTAL
Intervention: P‐1 (5 RM load, 3‐min rest periods, lower total work)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: P‐2 (10 RM load, 1‐min rest periods, higher total work)
Number of subjects: 16

Group type: COMPARATOR
Intervention: P‐1
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Both HREPs
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: P‐2
Number of subjects: 16
Study: 7045615

Group type: COMPARATOR
Intervention: Combination chemotherapy alone
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combination chemotherapy plus BCG
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: DTIC plus BCG
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combination chemotherapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: BCG
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Higher peripheral lymphocyte counts
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Higher numbers of positive delayed hypersensitivity skin tests
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: PPD conversion from negative to positive during therapy
Number of subjects: 0
Study: 30870767

Group type: EXPERIMENTAL
Intervention: Transcutaneous spinal TENS
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Transcutaneous spinal stimulation at 10 kHz
Number of subjects: 24

Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 24
Study: 29298599

Group type: EXPERIMENTAL
Intervention: Vocational Enablement Protocol (VEP)
Number of subjects: 136

Group type: COMPARATOR
Intervention: Usual care (Control)
Number of subjects: 136
Study: 27090559

Group type: EXPERIMENTAL
Intervention: Targeted experience narratives (Study 2)
Number of subjects: 562

Group type: EXPERIMENTAL
Intervention: Representative experience narratives (Study 1)
Number of subjects: 562

Group type: COMPARATOR
Intervention: Control condition (no narratives)
Number of subjects: 562
Study: 24837306

Group type: EXPERIMENTAL
Intervention: Gluten-free diet (GFD)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Gluten-containing diet
Number of subjects: 40
Study: 22752889

Group type: EXPERIMENTAL
Intervention: Endoscopy < 12 hours
Number of subjects: 4478

Group type: COMPARATOR
Intervention: Endoscopy > 24 hours
Number of subjects: 4478
Study: 19460609

Group type: EXPERIMENTAL
Intervention: Clopidogrel administration before CABG
Number of subjects: 13819

Group type: COMPARATOR
Intervention: No clopidogrel administration before CABG (Control)
Number of subjects: 13819
Study: 17089420

Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Behavioral Weight Loss Treatment (BWLT)
Number of subjects: 80
Study: 16298489

Group type: EXPERIMENTAL
Intervention: 24% w/v sucrose
Number of subjects: 242

Group type: COMPARATOR
Intervention: Water (control)
Number of subjects: 242
Study: 12042269

Group type: EXPERIMENTAL
Intervention: Day 5/6 embryo transfer
Number of subjects: 0

Group type: COMPARATOR
Intervention: Day 2 embryo transfer
Number of subjects: 0
Study: 9797521

Group type: EXPERIMENTAL
Intervention: Transoesophageal echocardiography (TOE)
Number of subjects: 224
Study: 8758833

Group type: EXPERIMENTAL
Intervention: Acupuncture treatment (30 min daily for 10 days at points PC6, LI4, ST36, RN4 and symptomatic points bilaterally)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 40
Study: 2523770

Group type: EXPERIMENTAL
Intervention: Negative pressure breathing at -12 cmH2O for 80 minutes
Number of subjects: 6

Group type: COMPARATOR
Intervention: Control studies (identical conditions without negative pressure breathing)
Number of subjects: 6
Study: 6985

Group type: EXPERIMENTAL
Intervention: Oral diazepam
Number of subjects: 57

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Group exposure
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Individual exposure
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Anxiety evocation during treatment
Number of subjects: 57